- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03190096
Safety and Feasibility of Electrical Isolation of the Superior Vena Cava for Paroxysmal Atrial Fibrillation (SAFE-SVC)
Safety and Feasibility of Electrical Isolation of the Superior Vena Cava in Addition to Pulmonary Vein Ablation for Paroxysmal Atrial Fibrillation Using the Cryoballoon: the SAFE-SVC Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Consecutive patients programmed for cryoballoon ablation (CBA) for PAF will be prospectively enrolled in our study. After PVI is obtained and proven by entrance- and exit block, the SVC will be mapped for potentials. If the SVC exhibits electrical activity, isolation will be attempted performing a single maximum 180 seconds balloon application. A single 180 seconds application is known to produce a durable lesion. Performing a combined approach (PVI together with SVC isolation) using the same cryoballoon requires no additional vascular access. Therefore no significant raise in complications is to be expected. During a second generation CBA the described rate of complications is to be estimated around 2%. Transient phrenic nerve palsy in 7.2 %, but reversible in virtually all patients within the end of the procedure.
To prevent nervous injury the phrenic nerve (PN) will be tested during ablation of the SVC, in the same fashion as performed systematically during ablation of the right sided pulmonary veins.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Maria Salomone, MD
- Phone Number: +390545217031
- Email: msalomone@esrefo.org
Study Contact Backup
- Name: Saverio Iacopino, MD
- Phone Number: +390545217228
- Email: iacopino@iol.it
Study Locations
-
-
-
Brussels, Belgium
- Not yet recruiting
- UZ Brussel VUB
-
Contact:
- GianBattista Chierchia, MD,PhD
-
-
-
-
Ravenna
-
Cotignola, Ravenna, Italy, 48033
- Recruiting
- Maria Cecilia Hospital
-
Contact:
- Saverio Iacopino, MD
-
-
-
-
-
Nijmegen, Netherlands
- Not yet recruiting
- Radboud University
-
Contact:
- Sjoerd Westra, MD
-
-
-
-
-
Novosibirsk, Russian Federation
- Not yet recruiting
- Novosibirsk University
-
Contact:
- Alexander Romanov, MD,PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Written informed consent
- Consecutive patients programmed for cryoballoon ablation (CBA) for PAF will be prospectively enrolled in our study
Exclusion Criteria:
- Age younger than 18 years
- Severe valve disease (MI or AI > ¾)
- Uncontrolled heart failure,
- Contraindication to general anaesthesia/ deep procedural sedation
- Left atrial thrombus at the pre-procedural transesophageal echocardiogram (TEE)
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SVC isolation using a dedicated cryoballoon device
Time Frame: During procedure
|
feasibility and safety of superior vena cava (SVC) isolation added to standard pulmonary vein isolation using the cryoballoon in patients with paroxysmal atrial fibrillation
|
During procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical outcame
Time Frame: 12 months
|
Clinical outcome in terms of freedom from atrial fibrillation following ablation.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinically relevant abnormalities
Time Frame: 12 months
|
Detection of clinically relevant abnormalities on physical examinations, vital signs, 2D echocardio, 12 lead ECG, and laboratory routine tests.
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Saverio Iacopino, MD, Maria Cecilia Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ESREFO 31
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Paroxysmal Atrial Fibrillation
-
Medtronic Cardiac Rhythm and Heart FailureCompletedParoxysmal Atrial Fibrillation (PAF)United States, Canada
-
Biosense Webster, Inc.Active, not recruitingRefractory Paroxysmal Atrial FibrillationChina
-
Boston Scientific CorporationCompletedParoxysmal Atrial Fibrillation (PAF)United States, Spain, Germany, Australia, United Kingdom, Sweden, Czechia, France, Portugal
-
Biosense Webster, Inc.RecruitingDrug Refractory Paroxysmal Atrial FibrillationUnited States
-
Hospital Clinic of BarcelonaCompletedDrug-refractory Paroxysmal Atrial FibrillationSpain
-
Charite University, Berlin, GermanyGerman Federal Ministry of Education and ResearchTerminatedSymptomatic Paroxysmal Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Biosense Webster, Inc.CompletedDrug Refractory Symptomatic Paroxysmal Atrial FibrillationUnited States
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Atrial Fibrillation SolutionsCompletedSymptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart DiseasesNetherlands, Australia, France, Norway, Germany, Croatia, Italy, Argentina, Belgium
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
Clinical Trials on SVC isolation
-
AZ Sint-Jan AVRecruiting
-
Brigham and Women's HospitalBoston Scientific CorporationNot yet recruitingAtrial Fibrillation ParoxysmalUnited States
-
University of LeipzigRecruiting
-
Meshalkin Research Institute of Pathology of CirculationCompletedAtrial Fibrillation | Arterial HypertensionRussian Federation, United States, Greece
-
Boston Scientific CorporationWithdrawn
-
Liverpool Heart and Chest Hospital NHS Foundation...Boston Scientific CorporationRecruitingAtrial Fibrillation | Persistent Atrial FibrillationUnited Kingdom
-
Staedtisches Klinikum KarlsruheHeidelberg UniversityCompleted
-
Princess Amalia Children's ClinicCompleted
-
Royal Brompton & Harefield NHS Foundation TrustNot yet recruitingPersistent Atrial Fibrillation
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting